Demonstrated Safety Profile in MEfRVO
The most common adverse reactions (≥5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain,
cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.1
VIBRANT, COPERNICUS, and GALILEO:
Most common adverse reactions (≥1%)1
1 / 3
2 / 3
3 / 3
3 / 3
Less common adverse reactions reported in
<1% of the patients treated with EYLEA in the
CRVO studies were corneal edema, retinal tear, hypersensitivity, and endophthalmitis.1
Find out more about all
EYLEA indications
Get information about navigating the reimbursement process. Find enrollment forms, learn about PA assistance, and more.
